American Epilepsy Society Annual Meeting (AES)

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

The registry is planning to expand, with 5 additional centers recently agreeing to participate and institutional research ethics applications underway.

Effect modification analysis showed that the treatment effect when using CBD was comparable between patients with and without infantile spasm history.

The neurologist from Cleveland Clinic discussed the potential of using perampanel as a monotherapy for patients with focal onset seizures.

Data from this post-hoc analysis show slight differences between repeated administration of 1 and 2 doses of midazolam.

No patient with CDKL5 Deficiency Disorder developed valvular heart disease or pulmonary arterial hypertension while being treated with fenfluramine.

Interim data from a real-world study suggest that adjunctive treatment with brivaracetam is well-tolerated and may improve quality of life over 12 months for those with focal seizures.

The data suggest that some patients with partial-onset seizures may benefit from lower doses to mitigate treatment emergent adverse events, but these must be tailored to each patient.

The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado detailed the results of study of fenfluramine in patients with Lennox-Gastaut syndrome.

The safety profile of diazepam remained similar to what was previously observed, but generally, more patients in the concomitant benzodiazepine subgroup experienced more TEAEs.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how high rates of seizure reduction were seen in treating drug resistant epilepsy.

Top line results from the retrospective EXPERIENCE study of brivaracetam are expected to read out in early 2021.

The GW Pharmaceuticals product has shown confirmed efficacy in LGS, though the study failed to produce a firm conclusion regarding its efficacy in other drug-resistant epilepsies.

The director of pediatric epilepsy at the Northeast Regional Epilepsy Group discussed his study presented at AES 2020 which involved the effectiveness of diazepam nasal spray regardless of treatment regimen.

Zogenix’s fenfluramine (Fintepla) appears to provide durable and profound reductions in monthly convulsive seizure frequency for those with Dravet syndrome out to 3 years.

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

The neurologist from Cleveland Clinic discussed initial data from Study 410 and patient compliance rates with perampanel treatment.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.

The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine discussed the difficult treatment decisions faced when undergoing epilepsy surgery.

The director of the Pediatric Epilepsy Program and an MD candidate at Weill Cornell Medicine detail the steps needed to take to improve outcomes in status epilepticus.

Page B. Pennell, MD, president of the American Epilepsy Society, shared her thoughts on the epilepsy treatment landscape, managing women with epilepsy, and the need for multidisciplinary involvement and communication.

The president of the American Epilepsy Society and director of epilepsy research at Brigham and Women’s Hospital outlined the state of epilepsy care and what we can expect in 2020.

The director of the Pediatric Epilepsy Program is joined by an MD candidate from Weill Cornell Medicine to discuss the protocol used to treat patients with status epilepticus.

The epilepsy fellow at the hospital of the University of Pennsylvania detailed why locating the seizure onset zone plays a crucial role in successful epilepsy surgery.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine detailed the ongoing questions about assessing the gaps in breastfeeding between women with, and without, epilepsy.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the findings of the MONEAD study and their implications for women with epilepsy.

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital shared his insight into the potential of using an SCN1A-targeted adeno-associated viral vector-based gene therapy in epilepsy.